Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ACIU with free AI briefings, catalyst countdowns, and dilution alerts.

ACIU · AC Immune SA

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$73.9M Cash on Hand
CF+ Cash Runway
6.3% Short Interest
$8.99 Analyst Target (4)
Follow ACIU by email Get an email when ACIU reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACIU, unsubscribe in one click. Privacy

📣 What ACIU Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
JACI-35.054 Alzheimer's Disease Phase 1/2 · NCT04445831 Completed
ACI-7104.056 at Dose C (optional) Parkinson Disease Phase 2 · NCT06015841 Active not recruiting
ACI-7104.056 at Dose B (optional) Parkinson Disease Phase 2 · NCT06015841 Active not recruiting
ACI-7104.056 at Dose A Parkinson Disease Phase 2 · NCT06015841 Active not recruiting
ACI-35.030 Alzheimer's Disease Phase 1/2 · NCT04445831 Completed
ACI-24.060 at Dose C in Study Amyloid Plaque Phase 1/2 · NCT05462106 Recruiting
ACI-24.060 at Dose B in Study Amyloid Plaque Phase 1/2 · NCT05462106 Recruiting
ACI-24 Down Syndrome Phase 2 · NCT04373616 Withdrawn
ACI-24.060 at Dose A in Study Amyloid Plaque Phase 1/2 · NCT05462106 Recruiting
ACI-19764 at dose C1 Healthy Participants Phase 1 · NCT07463196 Recruiting
ACI-19764 at dose B3 Healthy Participants Phase 1 · NCT07463196 Recruiting
ACI-19764 at dose B2 Healthy Participants Phase 1 · NCT07463196 Recruiting
ACI-19764 at dose B1 Healthy Participants Phase 1 · NCT07463196 Recruiting
ACI-19764 at dose A6 Healthy Participants Phase 1 · NCT07463196 Recruiting
ACI-19764 at dose A5 Healthy Participants Phase 1 · NCT07463196 Recruiting
ACI-19764 at dose A4 Healthy Participants Phase 1 · NCT07463196 Recruiting

Also used in these trials (approved or third-party drugs, not ACIU's own candidates): ACI-24.060 with an additional adjuvant at Dose E in Study, ACI-24.060 with an additional adjuvant at Dose D in Study.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACIU holds $73.9M in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACIU files for a raise →

👥 Who Owns ACIU

Insiders 4.4% Institutions 24.2% Public and other holders 71.4%
HolderTypeShares% of sharesAs of
BVF Inc. Institution (13F) 19,822,436 19.48% 2025-12-31
Andrea Pfeifer
Chief Executive Officer, Director
Insider 3,834,288 3.77% 2026-05-15
Wells Fargo & Company Institution (13F) 1,006,289 0.99% 2025-12-31
Millennium Management Llc Institution (13F) 933,342 0.92% 2025-12-31
Renaissance Technologies, LLC Institution (13F) 668,867 0.66% 2025-12-31
Blackrock Inc. Institution (13F) 502,169 0.49% 2025-12-31
Acadian Asset Management. LLC Institution (13F) 464,697 0.46% 2025-12-31
Point72 Asset Management, L.P. Institution (13F) 384,845 0.38% 2025-12-31
Arrowstreet Capital, Limited Partnership Institution (13F) 375,623 0.37% 2025-12-31
Northern Trust Corporation Institution (13F) 281,953 0.28% 2025-12-31
Dimensional Fund Advisors LP Institution (13F) 213,464 0.21% 2025-12-31
Christopher James Roberts
Chief Financial Officer
Insider 155,382 0.15% 2026-03-18

Share count 101,742,231 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-06-11
filed 2026-06-15
Twyman Roy Ervin
Option award (A) 38,889 – –
2026-06-11
filed 2026-06-15
Twyman Roy Ervin
Award (A) 16,568 – 92,556
2026-06-11
filed 2026-06-15
Buetler Monika
Option award (A) 41,667 – –
2026-06-11
filed 2026-06-15
Buetler Monika
Award (A) 17,751 – 71,656
2026-06-11
filed 2026-06-15
June Carl Howard
Option award (A) 38,889 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ACIU picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACIU and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.